IRegene Therapeutics Receives FDA RMAT Designation for NouvNeu001 in Parkinson’s Disease
Tuesday, January 20, 2026
iRegene Therapeutics has announced that its lead product, NouvNeu001, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for the treatment of Parkinson’s disease.
Parkinson’s disease is the second most common neurodegenerative disorder worldwide. Current treatment options mainly focus on symptom control and do not address the underlying loss of dopaminergic neurons.
NouvNeu001 has been developed to overcome this limitation. It is an allogeneic iPSC-derived dopaminergic progenitor cell therapy designed to replace lost neurons, rebuild damaged neural circuits, and restore the body’s ability to produce dopamine naturally. By addressing the biological cause of the disease rather than only its symptoms, the therapy aims to offer a disease-modifying approach that could change current treatment standards.
With this decision, NouvNeu001 becomes the first allogeneic induced pluripotent stem cell (iPSC)-derived therapy worldwide to receive both FDA Fast Track Designation (granted in August 2025) and RMAT designation. These regulatory milestones reflect the FDA’s confidence in the therapy’s early clinical data, innovative development platform, and potential to address an unmet medical need in Parkinson’s disease.
RMAT designation was introduced under the 21st Century Cures Act to speed up the development and review of regenerative medicines intended to treat serious or life-threatening conditions. Therapies with RMAT status benefit from closer interaction with the FDA and may be eligible for accelerated approval and priority review. This pathway is expected to help shorten development timelines and support faster access for patients.
Together, these programmes highlight iRegene’s long-term strategy to develop scalable, safe, and effective cell-based treatments across multiple disease areas, with the aim of improving outcomes for patients with limited therapeutic options.
Source: prnewswire.com
